Literature DB >> 15023813

A preliminary diffusion tensor and magnetization transfer magnetic resonance imaging study of early-onset multiple sclerosis.

Domenico M Mezzapesa1, Maria A Rocca, Andrea Falini, Maria E Rodegher, Angelo Ghezzi, Giancarlo Comi, Massimo Filippi.   

Abstract

BACKGROUND: Early-onset multiple sclerosis (MS) typically has a more favorable course than adult-onset disease.
OBJECTIVE: To assess the extent of microscopic tissue damage in the brain and cervical cord of patients with early-onset MS.
DESIGN: During a single magnetic resonance imaging session, images of the brain and spinal cord were obtained using diffusion tensor and magnetization transfer magnetic resonance imaging. PATIENTS: We studied 13 patients with early-onset MS and 10 healthy volunteers.
RESULTS: Compared with control subjects, patients with early-onset MS showed only a slight increase of the average mean diffusivity of the normal-appearing brain tissue.
CONCLUSION: The relatively modest central nervous system damage detected in these patients might explain why early-onset MS typically has a more favorable clinical course than adult-onset MS.

Entities:  

Mesh:

Year:  2004        PMID: 15023813     DOI: 10.1001/archneur.61.3.366

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis.

Authors:  P Tortorella; M A Rocca; D M Mezzapesa; A Ghezzi; L Lamantia; G Comi; M Filippi
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

2.  Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients?

Authors:  Maria A Rocca; Martina Absinta; Angelo Ghezzi; Lucia Moiola; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

3.  Tract-based analysis of callosal, projection, and association pathways in pediatric patients with multiple sclerosis: a preliminary study.

Authors:  M S Vishwas; T Chitnis; R Pienaar; B C Healy; P E Grant
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-22       Impact factor: 3.825

Review 4.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

Review 5.  MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.

Authors:  Massimo Filippi; Maria Assunta Rocca
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

6.  A comparative assessment of cerebral white matter by magnetization transfer imaging in early- and adult-onset multiple sclerosis patients matched for disease duration.

Authors:  Kader K Oguz; Asli Kurne; Aysegul Oz Aksu; Aslihan Taskiran; Erdem Karabulut; Rana Karabudak
Journal:  J Neurol       Date:  2010-03-11       Impact factor: 4.849

7.  Early white matter changes in childhood multiple sclerosis: a diffusion tensor imaging study.

Authors:  A Blaschek; D Keeser; S Müller; I K Koerte; A Sebastian Schröder; W Müller-Felber; F Heinen; B Ertl-Wagner
Journal:  AJNR Am J Neuroradiol       Date:  2013-05-16       Impact factor: 3.825

Review 8.  Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve.

Authors:  Massimo Filippi; Maria A Rocca
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

9.  Neural diffusion tensor imaging metrics correlate with clinical measures in people with relapsing-remitting MS.

Authors:  Abdulaziz Alshehri; Oun Al-Iedani; Jameen Arm; Neda Gholizadeh; Thibo Billiet; Rodney Lea; Jeannette Lechner-Scott; Saadallah Ramadan
Journal:  Neuroradiol J       Date:  2022-02-04

10.  DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications.

Authors:  Emilia Sbardella; Francesca Tona; Nikolaos Petsas; Patrizia Pantano
Journal:  Mult Scler Int       Date:  2013-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.